Tremfya (guselkumab) prior authorization denied appeal
IL-23 inhibitor for PsO, PsA, UC, Crohn's
Typical PA criteria
- Approved indication with ICD-10
- Prior systemic or biologic trial
- Specialist prescriber
- TB/HBV screening
Why your PA was denied
- Preferred IL-23 (often Skyrizi) not tried
- Prior systemic therapy not documented
- Anti-TNF step not met for IBD
- Screening absent
Evidence that overturns the denial
- ✓PASI, DAS28, HBI, or Mayo at baseline
- ✓Prior systemic/biologic trial documentation
- ✓Specialist letter
- ✓Screening labs
IBD indications (UC, Crohn's) added 2024+; verify current payer criteria for these newer indications.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Tremfya (guselkumab) prior authorization denied?+
The most common reasons are: Preferred IL-23 (often Skyrizi) not tried; Prior systemic therapy not documented; Anti-TNF step not met for IBD. Your denial letter names the specific criteria you did not meet.
How do I appeal a Tremfya (guselkumab) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Tremfya (guselkumab) denial?+
PASI, DAS28, HBI, or Mayo at baseline; Prior systemic/biologic trial documentation; Specialist letter.
What if the plan excludes Tremfya (guselkumab) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Zepbound (tirzepatide)
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Saxenda (liraglutide)